Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease

July 9, 2026 8:30 AM

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found